Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. - Wikidata - awgldk - TriplyDB

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

http://www.wikidata.org/entity/Q37691074

about

Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?Multiple Roles for B-Lymphocytes in Sjogren's Syndrome Treatment of primary Sjögren syndrome.Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.Rituximab in primary Sjögren's syndrome: a ten-year journey.The osteopontin transgenic mouse is a new model for Sjögren's syndrome Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Interferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?Significance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren's Syndrome.Current Approach to Dry Eye Disease.Biologic treatment in Sjögren's syndrome.A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker.Recommendations for the treatment of Sjögren's syndrome.Safety of treatments for primary Sjögren's syndrome.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.New Treatment Guidelines for Sjögren's Disease.Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.Sjögren Syndrome and Other Causes of Sicca in Older Adults.Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling.Patient burden of Sjögren's: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity.Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do.Current perspective on rituximab in rheumatic diseases.Interleukin-6/STAT pathway is responsible for the induction of gene expression of REG Iα, a new auto-antigen in Sjögren׳s syndrome patients, in salivary duct epithelial cells.Management of primary Sjögren's syndrome: recent developments and new classification criteria.European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.Efficacy of abatacept for IgG4-related disease over 8 months.Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?Sjögren syndrome

P2860

Q26753072-C0B09432-C97E-4EF2-9AA0-942D7327DA8B Q27022117-B11C63B6-2A2D-4EC3-A0CA-F48B85BE38E2 Q28068695-43F75B69-207D-4B59-A59C-1F644A14DD48 Q30249011-44C5F3D6-8AD9-4CCE-BDE5-83325574E91C Q30948155-AA13C990-FAA2-46C2-9E91-450B526C59CA Q34432465-CE76FCC3-2540-42FB-A3B7-0F1557750991 Q34457345-BEA6CE7B-EF97-480B-B4C1-13EFEBD273DF Q35196207-3A3F31E5-D7C6-47AE-9912-012A6FEC00BA Q35774612-C70DF99D-1B99-4BCA-B278-C96DDFB6F355 Q35953713-EEDC09E4-4E4E-470E-9311-7BD322479CCD Q36060629-C04CF188-40BA-491A-9293-791BC5CA8DF1 Q37703599-777AB75B-15EE-4291-83FF-73B339139B66 Q38235721-FEAA4B06-614C-4488-8C27-5E7E70045D3F Q38262453-5179DEB2-A5D9-4747-8E41-FFAB81F7B9AB Q38389487-ABB7D3A4-F63B-4EB2-B65C-A6F13346F3E4 Q38512291-FD9BAADE-4B2D-4149-B2AE-3F1D303CD1CB Q38584878-B75AA283-334B-4300-B6AD-0B105643D5C7 Q38711144-C51DBC7F-0A4F-4EEC-914C-5879CD871C5B Q38795404-4A7CC96A-4AB4-40D2-A891-B705D31CD5BC Q38840388-E5BDB6AC-D1FD-47C2-BD03-EBB012A4B818 Q38889818-366D03B0-B8AF-46A8-9D1C-D35691821652 Q38906337-A2F3F21A-94F8-4458-B595-0923B4E90491 Q39019614-2CE26235-B473-4D97-A3CB-67408C8D6B50 Q40799131-A17E71DE-D8C4-425C-AAE2-1AC670F02337 Q41687111-97EDABE1-500D-41E0-89FC-9FEE6DB475CA Q41928623-E0F283D0-5B0E-4009-9B61-D3EE53EBD88B Q42373160-B59013E2-7E46-4FAE-9EFB-F59DAB248969 Q46974371-955E9F22-0BAC-4EAA-9A1F-1B45BA526AA2 Q47700923-4ACA0C87-611B-4817-8EF4-00829563B9A3 Q49072027-65FA98A5-B030-440B-9132-D05EAE5D1AE5 Q53194059-0F92B591-A53A-4ECF-AFE8-5DA9ACC03853 Q53757214-26FFB4B5-6AFE-4D16-9570-0F10BEFA457F Q54310740-D094F2A9-3CFD-4680-B879-2BAAF60ED8EC Q54384919-2E5CF58F-9F37-416F-B8B2-592A2D4A1BB0 Q55970262-B6D6D2E3-14D1-4429-BE75-82EEBDA759C6

P2860

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

http://www.wikidata.org/entity/Q37691074

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@en

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@nl

type

label

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@en

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@nl

prefLabel

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@en

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@nl

P1433

Q37691074-BE0E11C4-196A-4404-8BB1-65A40125EBA5

P1476

Q37691074-D5546DD4-C823-4F68-8613-2D91AC40F934

P2093

Q37691074-01D571A1-1408-4D02-9ECF-A33EA97F8827

Q37691074-083986EC-8747-4C10-8CB1-E210A7752360

Q37691074-0931B022-5160-4844-AEC2-CE784DF128D2

Q37691074-2F2A75BE-A7D4-4579-A7B0-DFE82BF3B4DB

Q37691074-317DECEA-0859-4D93-9B9D-98739012FB19

Q37691074-3FC890F2-7A95-4802-AE5E-2DFC28040464

Q37691074-470F19F7-8DD2-4A48-AE88-4F80F9CB2FE5

Q37691074-50BAF996-C218-4FE8-B751-0B7C6DBCF796

Q37691074-5438258F-2934-4CE2-A35A-2F630FAC99B4

Q37691074-55270232-12A8-4F30-9B3E-33D0C1D99EF2

P2860

Q37691074-0632BDDF-699A-4205-943E-048E7D8A00C3

Q37691074-087E3C41-5005-4E3F-8690-C5C797C2DBAC

Q37691074-08A5F150-2992-4C2C-A44D-68F923D74580

Q37691074-0ABEE8C3-C311-400E-924C-7985B42334B5

Q37691074-0B724EB7-3F46-40F0-B70F-4C8BF7CC01CA

Q37691074-14E7DD42-7E2F-498B-813E-9EF303E8EAF8

Q37691074-1E4ED9ED-8C6E-4076-9953-F4211C6F4C35

Q37691074-1FAE6994-C3A8-4D91-9784-DFF069526C6F

Q37691074-3444F3F0-2B29-476C-B667-C639A1454BD3

Q37691074-3EDD98B2-46E8-4E7E-8165-C0FEC8DF107A

P2888

Q37691074-47E324E9-89A8-43CE-9F7F-D1152DCBA8F4

P304

Q37691074-ED1440D7-0FD7-470D-8074-903804684DE8

P31

Q37691074-7DECAE5C-71E6-4600-886C-00DEDE58BC90

P356

Q37691074-BF58123F-155A-4C1A-8401-7D89667F6CD7

P433

Q37691074-F317F774-4804-41D5-8FEE-B526DB56067F

P478

Q37691074-A8B9E7F2-D9D6-4C3B-B23A-ED130766CFEA

P50

Q37691074-1F1685C8-416B-4A6D-B94D-498C9BE8A52C

P577

Q37691074-59F79A96-FC08-466A-9C65-569C688241F6

P5875

Q37691074-0E5D28FD-B786-41CD-877D-C7A03A0BA242

P6179

Q37691074-4EC26EEC-DBBC-4B22-B58D-6E3BC7FDB102

P698

Q37691074-41495A01-10CE-406E-94EA-87B0503EE245

P932

Q37691074-66D707F4-E9B5-455A-AB6B-52A2F0035DAD

P356

P1433

Arthritis Research and Therapy

P1476

Efficacy and safety of rituxim ...... multi-center, follow-up study.

@en

P2093

Alessandra Marrelli

http://www.w3.org/2001/XMLSchema#string

Alessia Alunno

http://www.w3.org/2001/XMLSchema#string

Antonio Manzo

http://www.w3.org/2001/XMLSchema#string

Francesco Carubbi

http://www.w3.org/2001/XMLSchema#string

Francesco Ciccia

http://www.w3.org/2001/XMLSchema#string

Giovanni Triolo

http://www.w3.org/2001/XMLSchema#string

Ilenia Pantano

http://www.w3.org/2001/XMLSchema#string

Onorina Berardicurti

http://www.w3.org/2001/XMLSchema#string

Paola Benedetto

http://www.w3.org/2001/XMLSchema#string

Paola Cipriani

http://www.w3.org/2001/XMLSchema#string

P2860

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients.

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors

Role of chemokines in the development of secondary and tertiary lymphoid tissues.

B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.

P2888

P304

R172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR4359

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259001663

http://www.w3.org/2001/XMLSchema#string

P6179

1051159898

http://www.w3.org/2001/XMLSchema#string

P698

24286296

http://www.w3.org/2001/XMLSchema#string

P932

3979092

http://www.w3.org/2001/XMLSchema#string